Targeting brain cells to treat depression linked to chronic stress
Microglia-targeted glutaminase inhibition forthe treatment of chronic stress-associated depression
This study is looking at a new way to help people with depression linked to chronic stress by targeting a specific enzyme in the brain, hoping to reduce symptoms like feeling withdrawn or losing interest in things, and it could be especially helpful for those who haven't found relief with current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11047726 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating chronic stress-associated depression by focusing on a specific enzyme in brain cells called glutaminase. The study uses a rodent model to explore how inhibiting this enzyme can reduce symptoms of depression, such as social withdrawal and lack of pleasure. By using a selective inhibitor that targets only the problematic enzyme, the research aims to minimize side effects and improve treatment outcomes for patients resistant to current antidepressants.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing chronic stress and resistant to conventional antidepressant therapies.
Not a fit: Patients with depression not associated with chronic stress or those who do not respond to any form of antidepressant treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from chronic stress-related depression.
How similar studies have performed: Previous research has shown promise in targeting glutaminase for depression treatment, but this specific approach using a selective inhibitor is novel.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Zhu, Xiaolei — Johns Hopkins University
- Study coordinator: Zhu, Xiaolei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.